Prostatitis Therapeutics Pipeline

Prostatitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS11315
Available Format:
Pages: 42

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation


The term prostatitis is defined as microscopic inflammation of the tissue of the prostate gland and it occurs due to a broad range of clinical conditions. The symptoms of prostatitis include difficulty urinating, pelvic area or genitals, pain in the groin, and, sometimes, flu-like symptoms. In 2008, through various studies in the U.S., it was estimated that the prevalence of prostatitis ranges between 2.2% to 9.7%. Due to increased risk of sexually transmitted disease, people become more susceptible to prostatitis. The treatment of prostatitis depends on the underlying cause and can include, antibiotics, alpha blockers, and anti-inflammatory agents. Antibiotics is the most commonly prescribed treatment for prostatitis. The choice of antibiotics depends on the type of bacteria that might be causing the infection. Intravenous antibiotics are given in severe infections and oral antibiotics are given for four to six weeks for chronic or recurring prostatitis.




Ibuprofenamine has reached the Phase III stage of development for the treatment of prostatitis. It is projected that the drug would be launched commercially in coming years for the treatment of prostatitis.

Pipeline Analysis

As of November 2017, the prostatitis therapeutics pipeline comprises of total 11 drug candidates in various stages of development.

Competitive Landscape

Some of the key players developing drugs for the treatment of prostatitis therapeutics include Angelini Acraf SpA, TFPHARMA, and Aquinox Pharmaceuticals, Inc.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 1850
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 2500
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 5000

Pre-Purchase Enquiry